![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1741302
½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°Sprycel Market, By Application, By Age Group, By Distribution Channel:, By Region |
½ºÇÁ¶óÀ̼¿ ½ÃÀåÀº 2025³â¿¡ 23¾ï 4,000¸¸ ´Þ·¯, 2032³â¿¡´Â 28¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 2.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 23¾ï 4,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR : | 2.80% | 2032³â °¡Ä¡ ¿¹Ãø | 28¾ï 4,000¸¸ ´Þ·¯ |
½ºÇÁ¶óÀ̼¿Àº ´Ù»çƼ´ÕÀÇ »óǰ¸íÀ¸·Î, ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ¾àÁ¦ÀÔ´Ï´Ù. Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹° Ŭ·¡½ºº°·Î ¼ÓÇÕ´Ï´Ù. ´Ù»çƼ´ÕÀº ¾Ï¼¼Æ÷ÀÇ Áõ½Ä°ú ÀüÀÌ¿¡ °ü¿©ÇÏ´Â È¿¼ÒÀΠƯÁ¤ Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ È°¼ºÀ» ÀúÇØÇÔÀ¸·Î½á ÀÛ¿ëÇÕ´Ï´Ù. ½ºÇÁ¶óÀ̼¿Àº ÁַΠƯÁ¤ À¯ÇüÀÇ ¹éÇ÷º´, ƯÈ÷ Çʶóµ¨ÇÇ¾Æ ¿°»öüÀÇ Á¸À縦 Ư¡À¸·Î ÇÏ´Â ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(ALL)(Ph ALL) ¹× ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML)ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â Ç¥Àû ¾à¹°ÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ÇÇ·Î, µÎÅë, ¸Þ½º²¨¿ò, ¼³»ç, ü¾× Àú·ù µîÀÌ ÀÖ½À´Ï´Ù. ȯÀÚ¿¡ µû¶ó Ç÷±¸ ¼ö °¨¼Ò, °£Àå¾Ö, ÃâÇ÷ µî º¸´Ù ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀ» °ü¸®ÇÏ°í ´ëóÇϱâ À§Çؼ´Â °Ç° °ü¸® Á¦°ø¾÷üÀÇ ¸é¹ÐÇÑ ¸ð´ÏÅ͸µÀÌ Áß¿äÇÕ´Ï´Ù. CML·Î Áø´ÜµÈ 12°³¿ù ÀÌ»óÀÇ ¼ºÀΰú ¼Ò¾Æ ¸ðµÎ¿¡°Ô Åõ¿©µË´Ï´Ù. ¶ÇÇÑ, Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¶Ç´Â Ph ALL·Î ¾Ë·ÁÁø ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ÀÇ Æ¯Á¤ ¾ÆÇüÀ» ¾Î°í ÀÖ´Â °°Àº ¿¬·ÉÃþÀÇ ¼ºÀÎ ¹× ¼Ò¾Æ¿¡°Ôµµ ó¹æµË´Ï´Ù. ¹éÇ÷º´Àº °ñ¼ö¿¡¼ ¹ß»ýÇÏ´Â ¹Ì¼º¼÷ ¹éÇ÷±¸°¡ °ü¿©ÇÏ´Â ¾Ç¼º Á¾¾çÀÔ´Ï´Ù. Á¤»óÀûÀÎ °úÁ¤¿¡¼ ÀÌ·¯ÇÑ ¹éÇ÷±¸°¡ ¼º¼÷ÇÏ¸é °¨¿°°ú ½Î¿ì°í ½ÅüÀÇ ¸é¿ª ü°è¸¦ À¯ÁöÇϱâ À§ÇØ Ç÷·ù·Î µé¾î°©´Ï´Ù.
Ç¥Àû ÀûÀÀÁõ Áõ°¡, È¿´É ¹× ¾ÈÀü¼ºÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõÀÇ È®´ë, Çõ½ÅÀûÀÎ Áøº¸´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥Àû ¿ä¹ýÀÇ °³¹ßÀ» Æ÷ÇÔÇÑ ¾Ï ¿¬±¸¿Í Ä¡·áÀÇ Áøº¸·Î ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀÌ È®´ëµÇ¾ú½À´Ï´Ù. ÀÌ ¶§¹®¿¡ Ä¡·á ¿ä¹ýÀÇ ÀÏȯÀ¸·Î ½ºÇÁ¶óÀ̼¿ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
±×·¯³ª °·ÂÇÑ °æÀï, ƯÇã ¸¸·á, ±ÔÁ¦ °úÁ¦, ºÎÀÛ¿ë, °¡°Ý ¹× »óȯÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Sprycel Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 2.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 2.8% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 2.34 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 2.80% | 2032 Value Projection: | USD 2.84 Bn |
Sprycel is the brand name for dasatinib, a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib works by inhibiting the activity of specific tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. Sprycel is a targeted medication primarily employed in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL), characterized by the presence of the Philadelphia chromosome (Ph+ ALL), and chronic myeloid leukemia (CML). Common side effects of Sprycel may include fatigue, headache, nausea, diarrhea, and fluid retention. Some patients may also experience more serious side effects, such as low blood cell counts, liver problems, and bleeding. Close monitoring by healthcare providers is important to manage and address any adverse effects. It is administered to both adults and children aged 12 months and older who are diagnosed with CML. Additionally, it is prescribed for adults and children in the same age group who are afflicted with a specific subtype of acute lymphoblastic leukemia known as Philadelphia chromosome-positive or Ph+ ALL. Leukemia is a malignancy involving immature white blood cells that develop within the bone marrow. In the normal course of events, as these white blood cells mature, they enter the bloodstream to combat infections and maintain the body's immune system.
The increasing prevalence of targeted indications, their efficacy and safety profile, expanded indications, and innovative advancements are major factors expected to drive growth of the global sprycel market during the forecast period. Advancements in cancer research and treatment, including the development of targeted therapies like Sprycel, have expanded the options available to healthcare providers and patients. This has led to increased adoption of Sprycel as part of the treatment regimen.
However, strong competition, patent expiration, regulatory challenges, adverse effects, and pricing and reimbursement are expected to hamper the growth of the global Sprycel market over the forecast period.